InsidersTradesSigma
Total declarations
Companies
▲ Purchases (14 ops.)
▼ Sales (45 ops.)
Explore the detailed record of transactions filed by BPIFRANCE INVESTISSEMENT SAS, Director. Director active across 20 companies, notably MAAT PHARMA. In total, 102 filings have been recorded. Total volume traded: €926.6m. The latest transaction was filed on 25 November 2025 — Souscription. Regulator: AMF. All data is accessible without signup.
Declarations102 total
€3m1,250,000 shares@ €2.40100.0% of flow
ActionHors plateforme de négociation
2025DD1071864·
€1m431,034 shares@ €3.486.4% of flow
ActionHors plateforme de négociation
2025DD1070137·
€999,999740,740 shares@ €1.3550.0% of flow
ActionHors plateforme de négociation
2025DD1049019·
€10m24,390,243 shares@ €0.4137.8% of flow
ActionHors plateforme de négociation
2025DD1044582·
€160m6,900,000 shares@ €23.262.85% mcap71.3% of flow
ActionEuronext Paris
2025DD1041573·
€53,98553,985 shares@ €1.001.3% of flow
ActionEuronext Growth Paris
2025DD1037651·
€5m819,672 shares@ €6.1021.2% of flow
ActionEuronext Paris
2025DD1028072·
€266m6,674,470 shares@ €39.850.68% mcap87.0% of flow
ActionEuronext Paris
2025DD1020350·
€126m4,200,000 shares@ €30.001.50% mcap100.0% of flow
ActionHors plateforme de négociation
2024DD1007389·
€2m1,602,410 shares@ €1.1046.8% of flow
ActionHors plateforme de négociation
2024DD989511·
01,818,181 shares0
cession de Droit Préférentiel de SouscriptionHors plateforme de négociation
2024DD987027·
Ideal exit: 5 Apr 2025 (T+270)
€2m1,818,181 shares@ €1.1053.2% of flow
ActionHors plateforme de négociation
2024DD987028·
01,818,181 shares0
cession de Droit Préférentiel de SouscriptionHors plateforme de négociation
2024DD987026·
€6m670,000 shares@ €8.2099.56% mcap100.0% of flow
ActionHors plateforme de négociation
2024DD985784·
€1m2,500,000 shares@ €0.4024.0% of flow
ActionHors plateforme de négociation
2024DD982319·
€15m1,153,982 shares@ €13.0014.8% of flow
ActionHors plateforme de négociation
2024DD969352·
€4m315,687 shares@ €13.004.1% of flow
ActionHors plateforme de négociation
2024DD971663·
€27m1,200,000 shares@ €22.320.47% mcap11.9% of flow
ActionHors plateforme de négociation
2024DD971123·
€1m37,808 shares@ €26.480.0025% mcap0.3% of flow
ActionEuronext Paris
2024DD969043·
0
ActionEuronext Paris
2024DD970881·
€75m5,769,094 shares@ €13.0074.1% of flow
ActionHors plateforme de négociation
2024DD969353·
€8m1,000,000 shares@ €8.0034.0% of flow
ActionEuronext Paris
2024DD966207·
€300,08920,269 shares@ €14.80530.0053% mcap0.1% of flow
ActionEuronext Paris
2024DD957979·
Ideal exit: 28 Dec 2024 (T+270)
€10m600,000 shares@ €17.250.18% mcap4.6% of flow
ActionEuronext Paris
2023DD941672·
Ideal exit: 31 Aug 2024 (T+270)
0500 shares0
ActionHors plateforme de négociation
2023DD939450·
25 of 102 declarations
About BPIFRANCE INVESTISSEMENT SAS
Bpifrance Investissement SAS is the investment arm of Bpifrance and a major institutional shareholder in French listed companies. Its role is typically not that of an operating executive, but of a long-term investor and governance partner, acting through board seats, supervisory board memberships, or censeur mandates. Public disclosures show that it has active roles in listed companies including MaaT Pharma, Fermentalg, SergeFerrari Group, Voyageurs du Monde, and Advicenne. At MaaT Pharma, Bpifrance Investissement SAS is a significant shareholder and has stated in AMF filings that it intended to continue purchasing shares as part of a long-term investment posture. This position is consistent with support for the company’s clinical and industrial development in microbiome-based therapeutics. At Fermentalg, Bpifrance Investissement SAS also appears as an important shareholder, reflecting a durable commitment to companies operating in biotechnology and sustainable bio-industrial solutions. The market data and insider-trading disclosures confirm an ongoing presence in the shareholding structure. With SergeFerrari Group, Bpifrance Investissement SAS is reported as a member of the supervisory board and has made market-notified share transactions. This suggests a hands-on governance role and continued monitoring of its investment, while remaining aligned with a minority, strategic shareholder profile. At Voyageurs du Monde, Bpifrance Investissement SAS holds a censeur mandate through a fund it manages, with a permanent representative who is an employee of Bpifrance Investissement. This structure gives it an observer and governance role rather than direct operational control, but still places it close to strategic and financial decision-making. At Advicenne, Bpifrance Investissement SAS serves as a board director and has explicitly stated that it does not intend to take control of the company. This is consistent with its model as a long-term, patient capital provider focused on value creation, governance support, and shareholder stability. Overall, Bpifrance Investissement SAS is best characterized as a sophisticated French growth investor with strong experience in listed-company governance, capital development, and strategic support. Its portfolio presence across biotechnology, industrial materials, travel, and specialty healthcare illustrates a diversified investment approach grounded in innovation, long-term partnership, and French industrial resilience.
